Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

PLX8394

HY-18972

(PLX-8394)

PLX8394

PLX8394 Chemical Structure

PLX8394 is a potent and selective inhibitor of B-RafV600E (IC50~5 nM).

Size Price Stock Quantity
10 mM * 1 mL in DMSO $418 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €410 In-stock
5 mg €343 In-stock
10 mg €490 In-stock
50 mg €1470 In-stock
100 mg €2058 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: PLX8394
Cat. No.: HY-18972

PLX8394 Data Sheet

  • Network Version

    DataSheet

Related Compound Libraries

Biological Activity of PLX8394

PLX8394 is a potent and selective inhibitor of B-RafV600E (IC50~5 nM).
IC50 value: ~5 nM
Target: B-RafV600E
in vitro: PLX8394 potently inhibits phosphorylation of ERK1/2 in PRT #3 and PRT #4 cells in addition to parental cells. PLX8394 potently inhibits ERK1/2-driven GAL4-Elk1 reporter activity in PRT cells as well as parental cells. PLX8394 effectively reducs cyclin D3 and cyclin D1, phosphorylation of retinoblastoma protein, and expression of cyclin A2 in parental cells. PLX8394 reduces levels of these cell cycle markers in PRT #3 and PRT #4 cells. Consistent with these effects, PLX8394 inhibits EdU incorporation into PRT #3 and PRT #4 cells in S phase entry assays. PLX8394 inhibits ERK1/2 phosphorylation and the growth of vemurafenib-resistant cells harboring either a BRAF V600K/L505H double mutation or an transposon-induced, N-terminal truncated form of BRAF.

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 542.53 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C25H21F3N6O3S
CAS No 1393466-87-9
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.8432 mL 9.2161 mL 18.4322 mL
5 mM 0.3686 mL 1.8432 mL 3.6864 mL
10 mM 0.1843 mL 0.9216 mL 1.8432 mL

References on PLX8394

Inhibitor Kit

Related Raf Products

  • AZ 628

    AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.

  • B-Raf IN 1

    B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM; equipotent against c-Raf (IC50= 25 nM).

  • B-Raf inhibitor

    A B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases.

  • BRAF inhibitor

    BRAF inhibitor is a potent BRAF inhibitor.

  • GDC-0879

    GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well; no inhibition known to other protein kinases.

  • GW 5074

    GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.

  • HG6-64-1

    HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.

  • L-779450

    L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38(alpha), GSK3(beta) and Lck respectively.

  • LGX818

    LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.

  • LY3009120

    LY3009120 is a small molecule that has been shown in vitro to be a pan-RAF inhibitor of all isoforms, blocking proliferation in both BRAF and RAS mutant cells.

MORE